Quantitative Research: Practitioners, N=100; Payers, N=20
A specialty pharmaceutical company wanted to evaluate the potential of a late-stage
pipeline oral drug. The drug candidate had an attractive target product profile but was launching into a significantly genericized market.
Viscadia was asked to design and build a custom forecast model to clearly identify the risks and opportunities facing both the product and the wider market.
Qualitative IDIs: KOLS, N=4; Practitioners, N=12; Payers, N=4
Quantitative Research: Practitioners, N=100; Payers, N=20
Identified relevant analogues to develop a perspective on pricing and implications of the ensuing access constraints on product uptake
Evaluated near-term future of the overall market, drawing on inputs from KOLs, practitioners and payers, and their positioning/ projected uptake for the product opportunity
© 2025 Viscadia Inc. All Rights Reserved. Privacy Policy Terms of Use